FDA delays review of BioMarin's hemophilia gene therapy after data update

Submitted by admin on March 7, 2023 - 11:16am

Source:

Endpoints

News Tags:

Biomarin

gene therapy

hemophilia A

FDA

valrox

Headline:

FDA delays review of BioMarin's hemophilia gene therapy after data update

snippet:

The FDA has extended its review of BioMarin’s gene therapy for hemophilia A by three months, formalizing an expected delay that will now push out a decision to the end of June.

Search form

You are here

FDA delays review of BioMarin's hemophilia gene therapy after data update

FDA delays review of BioMarin's hemophilia gene therapy after data update